About: Elke Pogge von Strandmann

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elke Pogge von Strandmann Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Attributes	Values
rdf:type	Item
description	forskare (sv) 연구원 (ko) araştırmacı (tr) изилдөөчү (ky) 研究者 (zh)
rdfs:label	Elke Pogge von Strandmann (de) Elke Pogge von Strandmann (en) Elke Pogge von Strandmann (es) Elke Pogge von Strandmann (fr) Elke Pogge von Strandmann (nl) Elke Pogge von Strandmann (ast)
skos:prefLabel	Elke Pogge von Strandmann (de) Elke Pogge von Strandmann (en) Elke Pogge von Strandmann (es) Elke Pogge von Strandmann (fr) Elke Pogge von Strandmann (nl) Elke Pogge von Strandmann (ast)
name	Elke Pogge von Strandmann (de) Elke Pogge von Strandmann (en) Elke Pogge von Strandmann (es) Elke Pogge von Strandmann (fr) Elke Pogge von Strandmann (nl) Elke Pogge von Strandmann (ast)
given name	wds:Q47008822-ABA9E344-1150-4028-919E-A66D93F43388
given name	Elke
instance of	wds:Q47008822-4C0ED8DA-283F-491D-8750-076462C1650B
instance of	Homo sapiens
occupation	wds:Q47008822-D870CE3B-6B9E-4340-AAC4-EAAA9E1FCD9E
sex or gender	wds:Q47008822-BBA7F395-BF57-4FD2-A389-BBE1B92D551C
ISNI	wds:Q47008822-90e5913f-4ea0-3d19-373e-ab8e25877db4
VIAF ID	wds:Q47008822-85e57d46-4752-6f0e-38e4-9d47436b853f
GND ID	wds:Q47008822-539a2e13-4d7a-855a-7b67-4772122938ed
WorldCat Identities ID (superseded)	wds:Q47008822-1D0E74BB-543A-4DA7-9D4B-5D1729B7A615
VIAF ID	http://viaf.org/viaf/314881103
GND ID	https://d-nb.info/gnd/1067910883
occupation	researcher
sex or gender	female organism
ISNI	0000000401231417
VIAF ID	314881103
GND ID	1067910883
WorldCat Identities ID (superseded)	viaf-314881103
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q47008822
is author of	Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3) Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphoma Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance Regulation of self-ligands for activating natural killer cell receptors A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma Evidence of Inbreeding in Hodgkin Lymphoma Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor The Unique Molecular and Cellular Microenvironment of Ovarian Cancer Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure Heritability estimates on Hodgkin's lymphoma: a genomic- versus population-based approach RIG-I activation induces the release of extracellular vesicles with antitumor activity Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell Plasticity Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNA to bystander cells NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia Antigen Loss Variants: Catching Hold of Escaping Foes Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity
is author of	wds:Q35053177-14B35F24-D909-4246-853C-D8FFAA35CAC9 wds:Q37876089-184793E1-58E1-4FE6-B2EE-7135FE56C75F wds:Q38739764-84D3E430-E02E-437A-9546-777BB1CB1D3B wds:Q39551912-E1FFC447-9ABE-41A1-92D5-117FA550D550 wds:Q40185345-64FA248C-4FD2-4616-A028-37871806B015 wds:Q40372471-D8071D1C-2475-4624-AAED-0CD97A7B0837 wds:Q40524771-BFAFC681-580B-4D6F-AA4B-6D7CEE436FCE wds:Q40575827-258BE291-726A-476C-8668-617DC769B823 wds:Q40425646-54C1E35D-A89A-4D4F-9ECF-1C23FB1EC2BD wds:Q36001617-7F3B8B39-8D38-4CF8-9707-37B17FB8295E wds:Q38726608-7B758A57-6A47-44CF-9409-25ECA66235B1

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software